BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Fulvestrant

An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.

295+ PubMed studies analyzed · 61 RCTs · Evidence Score: 58

Research Domains

Fulvestrant has been studied across 8 research domains including 🔬 Oncology, 🧬 Hormones, ⏳ Longevity & Aging, 😴 Sleep, 🫁 Liver & Detox. The primary research focus is 🔬 Oncology with 84% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Fulvestrant, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Levonorgestrel
17 shared targets
Norgestrel
17 shared targets
Norethindrone
15 shared targets
Gestrinone
16 shared targets
Stanozolol
13 shared targets
Itraconazole
12 shared targets
Dehydroepiandrosterone
13 shared targets
Dehydroepiandrosterone
13 shared targets
Spironolactone
15 shared targets
Pregnenolone
11 shared targets
Loading evidence profile...

This evidence profile for Fulvestrant is generated deterministically from 295 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.